Sanofi-Aventis
Moscow, Russia
NCT Number: NCT00397553
To provide local data on efficacy and safety of insulin glulisine in patients with Type 1 Diabetes Mellitus receiving insulin glargine as basic insulin therapy
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Moscow, Russia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Time frame: 52 weeks
Time frame: 26 weeks
Time frame: 26 weeks
Time frame: 52 weeks
Time frame: 26 weeks
Time frame: 52 weeks
Looking for future studies?
Notify MeSanofi
Industry
Multicenter, Open, Non-randomised Phase III Clinical Study of Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02402439
Autoimmune Diseases, Diabetes Mellitus
San Francisco, California, United States
View Trial DetailsNCT06229236
Autoimmune Diseases, Diabetes Mellitus
Baltimore, Maryland, United States
View Trial DetailsNCT07478211
Autoimmune Diseases, Diabetes Mellitus
Bern, Canton of Bern, Switzerland
View Trial DetailsNCT06809621
Autoimmune Diseases, Diabetes Mellitus
Neuss, Germany
View Trial Details